35 results about "Apoptosis related genes" patented technology

The invention discloses a gene chip for detecting the differential expression of human mitochondrial genes. The gene chip is to a glass substrate incubated with probes for detecting the transcriptional abundance of 9 tRNAs, 2 rRNAs and 13 mRNAs encoded by human mitochondrial genes, as well as 5 apoptosis-associated genes encoded by nuclear DNA(nDNA). The gene chip provided by the invention is capable of detecting simultaneously the differential expression of the whole human mitochondrial mtDNA and nDNA under two different conditions, and analyzing the inherent correlation; and the invention represents the minimization and specialization of gene chip technology, and accomplishes the detection on expression of human mitochondrial mtDNA and nDNA efficiently and conveniently.

The present invention is based, at least in part, on the discovery of methods useful in the modulation, e.g., inhibition, of gene expression or protein activity, e.g., apoptosis-related gene expression, e.g., Fas gene expression or cytokine expression, e.g., proinflammatory cytokine expression. In particular, the present invention is based on novel RNA interfering agents, e.g., siRNA in reduction, e.g., prolonged reduction, of apoptosis-related gene expression or cytokine expression in cells. Inhibition of apoptosis-related gene expression or protein activity or cytokine gene expression or protein activity, e.g. by the siRNAs used in the methods of the invention, inhibits ischemia-reperfusion injury.

Provided is an isolated polypeptide comprising a Cricetulus griseus sequence capable of mediating apoptosis of a cell, the sequence being selected from a FAIM sequence shown as SEQ ID NO: 1; a FADD sequence shown as SEQ ID NO: 2; a PDCD6 sequence shown as SEQ ID NO: 3; and a Requiem sequence shown as SEQ ID NO: 4.

The invention discloses a gene detection method of a sperm cell apoptosis related gene. The gene detection method is characterized in that detection of the sperm cell apoptosis related gene is provided for all subjects by simultaneously detecting and analyzing SNPs site gene portability of individual NOS3 gene and FASLG gene, and forecast evaluation on a male infertility risk is carried out by combining with unique environmental exposure factors and lifestyle factors related to azoospermia and oligospermia in Chinese population.

The invention discloses an application of mannitol in preparation of an anti-pancreatic cancer drug, and in particular relates to a use of a mannitol injection with a specific concentration of 10%-19% for treating pancreatic cancer. Traditionally, mannitol is only used as a diuretic, a high-permeability hypotensor and the like, while the inventor discovers through scientific experiments that mannitol has anti-tumor activity, and through several cell apoptosis detection technologies and by detecting apoptosis-related genes bcl-1, and bax, proves that the specific-concentration mannitol can induce various human cancer cell strains to generate obvious cancer cell apoptosis, grasps the effect relation with concentration and time, and first illustrates the possible mechanism; furthermore, the inventor has used the research result for tumor patient treatment and has achieved obvious curative effect, which provides theoretical basis and practical cases for the application of mannitol in preparation of the anti-tumor drug and the clinical generalization thereof.

The present invention relates the application of a human source dcf1 gene in the inhibition of U251 glioma cell line proliferation and in the induction of U251 glioma cell line apoptosis. The present invention makes judgments for dcf1-induced U251 cell line apoptosis by the methods of immune electron microscope, atomic force microscope, CCK8 proliferation detection, JC-1 staining, and nude mouce tumor heterotopic transplantation. The results show that: the dcf1 causes mitochondrial structure lesion and membrane potential reduction by locating in mitochondria, thereby causing apoptosis-related gene expression change, and eventually leading to apoptosis. The nude mouce experiments show that the dcf1 can significantly reduce glioma tumor volume and inhibit tumor growth.

The invention relates to siRNA for inhibiting caspase-3 gene expression. The sequence thereof is as follows: the sense strand: 5'-GAGTCTGACTGGAAAGCCGAA-3'and the anti-sense strand: 5'-TTCGGCTTTCCAGGAAGACTC-3'. When entering nerve cells, the siRNA can obviously improve the vitality of nerve cells, obviously reduce the expression of apoptosis-related genes, i.e. caspase-3, of the nerve cells, lower the apoptosis and necrosis rate of the nerve cells and obviously reduce the expression of Alzheimer marker protein APP and that of Tau protein. The siRNA is capable of efficiently and specifically inhibiting the expression of disease-related gene caspase-3 so as to cause the silencing of relevant disease genes, and carrying out effective knockout on the expression of target genes to achieve the therapeutic purpose. The invention can be used for preparing medicines for inhibiting the apoptosis of the nerve cells or curing neurodegenerative diseases.

The invention provides an apoptosis-related gene, the gene contains a base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2. The invention also provides a carrier containing at least one target sequence of RNA interference for inhibiting the apoptosis-related gene. The invention also provides a cell which contains the carrier. The invention also provides a drug for curing leukemia, and the drug contains an effective amount of the RNA interference target sequence, or the carrier (containing the RNA interference target sequence) or the cell. The gene applies the RNA interference technique to inhibit PNAS-2, and has obvious effect to the treatment of leukemia.

The invention relates to application of vanillin in preparation of drugs for treating/preventing bone matabolic diseases. The vanillin is used for inhibiting the propagation of osteoclasts, the formation of polynuclear mature osteoclasts and the bone crushing capability of the osteoclasts, promoting the apoptosis of mature osteoclasts and regulating and controlling differentiation, fusion and maturing genes and apoptosis related genes of the osteoclasts and has the effects of maintaining a bone stable state, preventing bone loss and maintaining bone density, and novel drugs are provide for treating/preventing osteoclast activity induced diseases.

The invention provides application of apoptosis-related genes in repeated implantation failure, and belongs to the technical field of biological medicine and molecular biology. According to the application of the apoptosis-related genes in repeated implantation failure, endometrial RNA-seq related data are called from a GEO database, a series of differential genes are screened out from a GSE92324 queue, finally, it is determined that abnormal expression of three apoptosis related genes, namely, CSRNP1, BIRC8 and ELAPOR1 is closely related to repeated implantation failure, verification is carried out through a verification queue (GSE71835), the apoptosis-related genes are proved to have a good diagnostic value for the repeated implantation failure, so that the apoptosis-related genes can be used as prediction and diagnosis markers and potential treatment targets of the repeated implantation failure, plays an important role in diagnosis and treatment of the repeated implantation failure, and has a good practical popularization and application value.

The invention discloses an application of mannitol in preparation of an anti-breast cancer drug, and in particular relates to a use of a mannitol injection with a specific concentration of 10%-19% for treating breast cancer. Traditionally, mannitol is only used as a diuretic, a high-permeability hypotensor and the like, while the inventor discovers through scientific experiments that mannitol has anti-tumor activity, and through several cell apoptosis detection technologies and by detecting apoptosis-related genes bcl-2, and bax, proves that the specific-concentration mannitol can induce various human cancer cell strains to generate obvious cancer cell apoptosis, grasps the effect relation with concentration and time, and first illustrates the possible mechanism; furthermore, the inventor has used the research result to tumor patient treatment and has achieved obvious curative effect, which provides theoretical basis and practical cases for the application of mannitol in preparation of the anti-tumor drug and the clinical generalization thereof.

The invention discloses an application of mannitol in preparation of an anti-stomach cancer drug, and in particular relates to a use of a mannitol injection with a specific concentration of 10%-19% for treating stomach cancer. Traditionally, mannitol is only used as a diuretic, a high-permeability hypotensor and the like, while the inventor discovers through scientific experiments that mannitol has anti-tumor activity, and through several cell apoptosis detection technologies and by detecting apoptosis-related genes bcl-2, and bax, proves that the specific-concentration mannitol can induce various human cancer cell strains to generate obvious cancer cell apoptosis, grasps the effect relation with concentration and time, and first illustrates the possible mechanism; furthermore, the inventor has used the research result for tumor patient treatment and has achieved obvious curative effect, which provides theoretical basis and practical cases for the application of mannitol in the preparation of the anti-tumor drug and the clinical generalization thereof.

The invention provides application of bifidobacterium longum BL21 and a microbial inoculum containing the bifidobacterium longum BL21 in preparation of products for preventing, relieving or treating colorectal cancer. The bifidobacterium longum BL21 has excellent acid-resistant and cholate-resistant capabilities and good cell adhesion capability, can improve the gene expression level of pro-apoptosis factors CASP3 and Bax and reduce the gene expression level of anti-apoptosis factors Bcl-xl and Bcl-2 by regulating the expression of genes related to apoptosis of the colorectal tumor cells of mice, induces apoptosis of the colorectal tumor cells of the mice, and can be used for preparing the bifidobacterium longum BL21. In addition, the bifidobacterium longum BL21 can be used for remarkably relieving the inflammatory response of the colon part of a colorectal cancer model mouse, relieving the oxidative stress injury of the colorectal cancer model mouse, improving the micro-ecological environment of intestinal flora and maintaining the intestinal health, so that the bifidobacterium longum BL21 can be used for remarkably relieving the inflammatory response of the colon part of the colorectal cancer model mouse. The method has a wide prospect in preparation of products for preventing or treating colorectal cancer.

The invention relates to an application of 3-carbonyl-20alpha-hydroxy-24-en-dammarane compound for inhibiting gastric cancer cell SGC-7901 and hepatoma cell BEL-7404. Experiments show that 3-carbonyl-20alpha-hydroxy-24-en-dammarane compound can inhibit the proliferation of gastric cancer cell SGC-7901 and hepatoma cell BEL-7404 with an obvious effect and can be used to prepare antineoplastics. Electrophoresis detection shows that by increasing the expression quantity of apoptosis-related gene Bax, the 3-carbonyl-20alpha-hydroxy-24-en-dammarane compound can improve the apoptosis of hepatoma cell BEL-7404.

The present invention discloses a preparation method of a duck natural immune enhancer based on a traditional Chinese medicine extract. The preparation method comprises the following steps: (1) establishment of a rutin standard curve; (2) extraction of astragalus membranaceus flavonoids; and (3) calculation of astragalus membranaceus flavonoid concentration. The provided duck natural immune enhancer based on the traditional Chinese medicine extract can significantly increase levels of duck serum cytokines of IL-1-beta, IFN-alpha and IFN-beta, up-regulates tissue expression levels of natural immune-related genes RIG-I, TLR3, TLR7, IFN-alpha, IFN-beta, IL-1-beta and TNF-alpha, inflammation-related genes COX2 and iNOS, and cell apoptosis-related gene Caspase3 in duck immune organs of liver, spleen, thymus and bursa of fabricius, and enhances duck natural immune response and disease resistance performance.

A novel apoptosis-associated gene p53AIPI is isolated by screening for a gene the expression of which is induced by p53. Since the protein encoded by this gene has an activity of inducing apoptosis, this gene is useful in developing effective therapeutic agents for cancer mediated by apoptosis. A method of screening for a compound controlling the induction of apoptosis which is expected as being useful in developing an apoptosis controlling agent.

The invention discloses an application of mannitol in preparation of an anti-gastric adenocarcinoma drug, and in particular relates to a use of a mannitol injection with a specific concentration of 10%-19% for treating gastric adenocarcinoma. Traditionally, mannitol is only used as a diuretic, a high-permeability hypotensor and the like, while the inventor discovers through scientific experiments that mannitol has anti-tumor activity, and through several cell apoptosis detection technologies and by detecting apoptosis-related genes bcl-1, and bax, proves that the specific-concentration mannitol can induce various human cancer cell strains to generate obvious cancer cell apoptosis, grasps the effect relation with concentration and time, and first illustrates the possible mechanism; furthermore, the inventor has used the research result for tumor patient treatment and has achieved obvious curative effect, which provides theoretical basis and practical cases for the application of mannitol in preparation of the anti-tumor drug and the clinical generalization thereof.

The invention belongs to the technical field of biology, and particularly relates to application of a New Wenshen Shengjing Decoction (NWSSJD) to promotion of early embryonic development by maintaining the low level of H3K4me3 in sperms. A sexually mature male mouse is molded with cyclophosphamide, and drenches NWSSJD for 30 days, the treated male mouse is mated with a super-excreted female mouse, the developmental rate of embryos is counted in each stage, the expression of H3K4me3 in sperms and the embryos in each stage is detected by using an immunofluorescence staining method, the expression of methylase SETD1B in blastocysts is detected by using Western blotting, and the expression of development-related genes (OCT-4, NANOG and CDX2) and apoptosis-related genes (BCL-2 and P53) in the blastocyst is analyzed through qRT-PCR, and the result is analyzed and shows that the NWSSJD can promote the development of the early embryo by maintaining the normal H3K4me3 modification level in the sperm and the early embryo and inhibiting the apoptosis of embryonic cells.

The invention proposes siRNA interfering Mroh7 gene expression and application, an interfering method and a drug thereof and belongs to the field of molecular biotechnology and genetic engineering. The siRNA is transfected in cells to regulate the Mroh7 gene expression, further affect the cell viability and regulate the normal expression of cell proliferation and apoptosis-related genes. Therefore, the siRNA interfering the Mroh7 gene expression is applied to the preparation of a drug for improving cell viability and regulating cell division and proliferation and apoptosis, and has high practical application value.